Vaginal and sexual health in patients with ER+/HER2-metastatic breast cancer (mBC)

被引：0
|
作者：
Shanahan, Kelly [1 ]
Sammons, Sarah [2 ]
Meisel, Jane L. [3 ]
Pluard, Timothy J. [4 ]
Kozlowski, Monica [5 ]
Carroll, Dominic [5 ]
Attias, Elizabeth [5 ]
机构：
[1] Metavivor Res & Support Inc, Annapolis, MD USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Emory Winship Canc Inst, Atlanta, GA USA
[4] St Lukes Canc Inst, Kansas City, MO USA
[5] Sermonix Pharmaceut, Columbus, OH USA
来源：
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY | 2023年 / 30卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
P-89
引用
下载
收藏
页码：1296 / 1296
页数：1
相关论文
共 50 条
  • [41] Phase Ib/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER+/HER2-metastatic breast cancer.
    Bardia, Aditya
    Modi, Shanu
    Gregor, Mariana Chavez-Mac
    Kittaneh, Muaiad
    Marino, Alyssa J.
    Matano, Alessandro
    Bhansali, Suraj
    Hewes, Becker
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2-metastatic breast cancer
    Pan, Meiyu
    Lin, Yan
    Liu, Yinhui
    Xu, Ruijuan
    Yang, Jin
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (09) : 1387 - 1397
  • [43] Efficacy and Safety of Palbociclib and Fulvestrant in Japanese Patients With ER+/HER2-Advanced/Metastatic Breast Cancer
    Seki, Hirohito
    Sakurai, Takashi
    Maeda, Yuka
    Oki, Naohiko
    Aoyama, Mina
    Yamaguchi, Ryou
    Tokuda, Toshiki
    Kaburagi, Takuji
    Okumura, Takehiro
    Karahashi, Tsuyoshi
    Nakajima, Kenichiro
    Higeta, Kaori
    Shimizu, Ken
    IN VIVO, 2019, 33 (06): : 2037 - 2044
  • [44] Outcomes of patients with ER+/HER2+non-metastatic breast cancer treated with trastuzumab without chemotherapy
    Nguy, Susanna
    Wu, S. Peter
    Oh, Cheongeun
    Gerber, Naamit K.
    CANCER RESEARCH, 2020, 80 (04)
  • [45] Real-world treatment patterns and outcomes in ER+/PR+/HER2+metastatic breast cancer (MBC) patients: A National Cancer Database analysis.
    Statler, Abby
    Nahleh, Zeina A.
    Hobbs, Brian
    Wei, Wei
    Gupta, Annie
    Blake, Cassann N.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [46] A Phase 2 Study of Abemaciclib in Patients (PTS) with Brain Metastases (BM) Secondary to HR+, HER2-Metastatic Breast Cancer (MBC)
    Anders, Carey
    Le Rhun, Emily
    Bachelot, Thomas
    Yardley, Denise
    Awade, Ahmad
    Conte, Pierre Franco
    Cabos, Peter
    Bear, Melissa
    Tolaney, Sarah
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 10 - 10
  • [47] Efficacy it eribulin in patients (pts) with metastatic breast cancer (MBC): A pooled Analysis by HER2 and ER status
    Kaufman, Peter
    Twelves, Chris
    Cortes, Javier
    Vandat, Linda T.
    Olivo, Martin
    He, Yi
    Awada, Ahmad
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (26)
  • [48] Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): a pooled analysis by HER2 and ER status
    Twelves, C.
    Cortes, J.
    Vahdat, L.
    Olivo, M.
    He, Y.
    Kaufman, P. A.
    Awada, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 261 - 262
  • [49] SU2C Phase Ib Study of pan-PI3K Inhibitor BKM120 Plus Aromatase Inhibitor Letrozole in ER+/HER2-Metastatic Breast Cancer (MBC).
    Mayer, I. A.
    Balko, J. M.
    Kuba, M. G.
    Sanders, M. E.
    Yap, J.
    Li, Y.
    Winer, E.
    Arteaga, C. L.
    CANCER RESEARCH, 2011, 71
  • [50] Is there a correlation between androgen receptor (AR) expression in metastatic breast cancer (MBC) ER+/Her2-and response to anti-estrogen treatment?
    Martinez, M. C. Riesco
    Hanna, W.
    Ghorab, Z.
    Warner, E.
    CANCER RESEARCH, 2013, 73
12345